Clin Lipidology. 2010;5(3):309-323. The usual starting dose of pitavastatin is 1 mg once daily. The dose should be adjusted at intervals of at least 4 weeks according to LDL-C levels, the goal of ...

This study aimed to assess the causal relationship between genetically proxied lipid-lowering drugs and skin cancers and psoriasis. Methods: Two-sample Mendelian randomization (MR) analysis was ...

Addressing dyslipidemia is crucial to reducing the burden imposed by cardiovascular disease. However, many current statins have major limitations. Moreover, innovative treatments need to address ...

Importantly, an imaging biomarker should also reflect and track the mechanism of the tested drug. For example, measurement of plaque lipid content would be an appropriate biomarker for studying ...

It is estimated that about 50% of atherosclerotic cardiovascular disease is not driven by LDL-cholesterol – the target of most lipid-lowering drugs, including statins and PCSK9 inhibitors like ...

H ealth outcomes in humans often show daily variations. For instance, morning vaccinations may trigger a more effective ...

MONCYTE Health, a diagnostics company based in Helsinki, has raised €1 million in a seed funding round to advance its ...

Alzheimer's disease, a devastating neurodegenerative condition that affects millions of people worldwide, may have found a ...

For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million ...

Research done in Sweden, published in December 2023, explores the association between the use of lipid-lowering medication, specifically statins, and cognitive decline in patients with Alzheimer's ...